BioCentury
ARTICLE | Company News

Shionogi gains Asian rights to SAGE-217

June 15, 2018 7:57 PM UTC

Shionogi & Co. Ltd. (Tokyo:4507) licensed exclusive rights to SAGE-217 from Sage Therapeutics Inc. (NASDAQ:SAGE) in Japan, Taiwan and South Korea to treat major depressive disorder (MDD).

Shionogi will pay Sage $90 million up front, with Sage eligible to receive development and commercial milestones of up to $485 million and tiered royalties averaging “in the greater than 20% range.”...

BCIQ Target Profiles

GABA A receptor